|Bid||76.30 x 900|
|Ask||76.31 x 800|
|Day's Range||76.04 - 83.94|
|52 Week Range||14.01 - 99.95|
|Beta (5Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2021 - Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.75|
Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.
Stocks of start-ups wielding tools like Crispr-Cas9 that allow companies to edit DNA and attack genetic diseases and cancer are suddenly hot. But the science is moving with incredible speed and the competition is rising.
The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.